Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Invasive aspergillosis in 2002: an update.

D P Kontoyiannis1, G P Bodey

  • 1Department of Infectious Diseases, Infection Control and Employee Health, Box 402, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. dkontoyi@mdanderson.org

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|April 17, 2002
PubMed
Summary

Invasive aspergillosis is a serious threat to immunosuppressed patients, with increasing incidence. Early diagnosis and new antifungal drugs offer hope for improved outcomes in managing this fungal infection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.

Transplantation and cellular therapy·2021
Same author

Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine.

The Journal of antimicrobial chemotherapy·2020
Same author

Immunosuppressed Adult Zebrafish Model of Mucormycosis.

Antimicrobial agents and chemotherapy·2018
Same author

Bronchoalveolar Lavage Fluid Cytology in Culture-Documented Invasive Pulmonary Aspergillosis in Patients with Hematologic Diseases: Analysis of 67 Episodes.

Journal of clinical microbiology·2018
Same author

A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017
Same author

How common is subsequent central nervous system toxicity in asymptomatic patients with haematologic malignancy and supratherapeutic voriconazole serum levels?

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2017

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Immunocompromised Host Research

Background:

  • Invasive aspergillosis is a life-threatening fungal infection, particularly in immunosuppressed patients.
  • The incidence of invasive aspergillosis has risen over the past two decades.
  • Risk factors include prolonged granulocytopenia, graft-versus-host disease, and corticosteroid use.

Purpose of the Study:

  • To review the current challenges and advancements in managing invasive aspergillosis.
  • To highlight the importance of environmental control measures in preventing Aspergillus exposure.
  • To discuss promising developments in early diagnosis and antifungal therapy.

Main Methods:

  • Review of existing literature on invasive aspergillosis in immunosuppressed populations.

Related Experiment Videos

  • Analysis of predisposing factors and environmental influences.
  • Examination of recent diagnostic and therapeutic innovations.

    • Main Results:

    • Invasive aspergillosis incidence is increasing despite medical advances.
    • Multiple host and environmental factors contribute to disease development.
    • New diagnostic tools and antifungal agents are emerging.

    Conclusions:

    • Invasive aspergillosis remains a critical concern for immunosuppressed patients.
    • Effective management requires a multi-faceted approach including infection control.
    • Advancements in diagnostics and therapeutics offer future hope.